Emily Rowell

Emily Rowell serves as the VP of Pharmacology and Translational Research at Enlaza Therapeutics since June 2022, following a role as Director of Translational Research at InhibRx from October 2018 to December 2022. Previous experience includes positions as Research Investigator at GNF, Principal Scientist and Sr. Scientist at VLST Corp, and a Senior Fellow at the University of Washington, where significant research focused on epigenetic mechanisms regulating Th17-specific genes. Emily Rowell's academic foundation includes a Ph.D. in Immunology from the University of Pennsylvania School of Medicine and a B.A. in Neuroscience from Colgate University. Additional experience encompasses biomedical technical editing and teaching roles, highlighting a strong commitment to research and education throughout a diverse career in the life sciences.